Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
MLNT Melinta Therapeutics		$0.48	$0.31 ▼ $10.10	$6.88M	4.16	713,628 shs	N/A
VBLT Vascular Biogenics	$5.46 -8.8%	$0.40	$0.10 ▼ $6.74	$423.91M	0.77	2.19 million shs	161,505 shs
VVUS VIVUS		$0.37	$0.44 ▼ $4.75	$7.33M	-0.84	1.44 million shs	2.03 million shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-88.78%
MLNT Melinta Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
VBLT Vascular Biogenics	0.00%	0.00%	0.00%	0.00%	+2,359.46%
VVUS VIVUS	0.00%	0.00%	0.00%	0.00%	0.00%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MLNT Melinta Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
MLNT Melinta Therapeutics	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
MLNT Melinta Therapeutics	$96.43M	0.00	N/A	N/A	$16.96 per share	0.00
VBLT Vascular Biogenics	$660K	642.29	N/A	N/A	$0.32 per share	17.06
VVUS VIVUS	$69.76M	0.00	N/A	N/A	($6.50) per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
MLNT Melinta Therapeutics	-$157.19M	-$17.72	N/A	N/A	N/A	-393.39%	-101.29%	-28.68%	N/A
VBLT Vascular Biogenics	-$32.30M	-$0.21	N/A	∞	N/A	N/A	-73.45%	-54.11%	N/A
VVUS VIVUS	-$31.50M	-$2.96	N/A	N/A	N/A	-39.28%	N/A	-12.18%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLNT Melinta Therapeutics	N/A	N/A	N/A	N/A	N/A
VBLT Vascular Biogenics	N/A	N/A	N/A	N/A	N/A
VVUS VIVUS	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
MLNT Melinta Therapeutics	1.11	1.03	0.72
VBLT Vascular Biogenics	N/A	4.63	4.63
VVUS VIVUS	N/A	0.43	0.28

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
MLNT Melinta Therapeutics	18.02%
VBLT Vascular Biogenics	0.96%
VVUS VIVUS	7.32%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
MLNT Melinta Therapeutics	60.30%
VBLT Vascular Biogenics	6.13%
VVUS VIVUS	12.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
MLNT Melinta Therapeutics	290	13.75 million	N/A	Optionable
VBLT Vascular Biogenics	7	77.64 million	72.88 million	Optionable
VVUS VIVUS	57	17.87 million	N/A	Optionable

VBLT, MLNT, VVUS, and ADMP Headlines

Source	Headline
	VIVUS Provides Update on Pipeline and Program Milestones markets.businessinsider.com - January 8 at 10:04 AM
	Shark research group to build new global headquarters in Jacksonville with help from state funding actionnewsjax.com - June 26 at 9:16 AM
	Metaview announces Answers, the world's first conversational AI for the interview process it.tmcnet.com - May 25 at 11:10 AM
	Pancrelipase (CAS 53608-75-6) Market 2023 \| Industry Growth ... - StreetBuzz news.google.com - May 12 at 2:58 AM
	Exploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journal news.google.com - May 12 at 2:58 AM
	Extensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPR news.google.com - May 11 at 8:54 AM
	Erectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journal news.google.com - May 11 at 8:54 AM
	Milestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswire news.google.com - May 11 at 8:54 AM
	Anti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journal news.google.com - May 11 at 3:54 AM
	Anti Obesity Drugs Market Future Industry Scope for New ... - Digital Journal news.google.com - May 11 at 3:54 AM
	This Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolution news.google.com - May 10 at 12:51 PM
	Prostatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journal news.google.com - May 9 at 6:48 AM
	This 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuit news.google.com - May 7 at 8:20 PM
	Porsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuit news.google.com - May 6 at 3:22 PM
	Increasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPR news.google.com - May 5 at 1:45 PM
	Nonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journal news.google.com - May 5 at 7:44 AM
	A Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpost news.google.com - May 2 at 10:24 AM
	Intraoperative Ultrasound Market Latest Trends, Techniques and Applications\|2023-2030 - openPR news.google.com - April 28 at 9:38 AM
	Build Your Own Case Study \| Obesity: Treating the Whole Patient - Healio news.google.com - April 27 at 8:14 PM
	Bladder Cancer Market Demand in Various industries and Significant for Various Regions\|2023-2030 - openPR news.google.com - April 27 at 3:10 PM
	Pediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insights news.google.com - April 27 at 10:10 AM
	Global Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPR news.google.com - April 26 at 7:33 AM
	Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPR news.google.com - April 25 at 2:02 AM
	What to Know About Obesity and Bone Health - Health Central news.google.com - April 24 at 4:02 PM

New MarketBeat Followers Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Melinta Therapeutics

NASDAQ:MLNT

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Vascular Biogenics

NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

VIVUS

NASDAQ:VVUS

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial